Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gary Aldrich

Physician Assistant, Surgical Cedar Rapids, IA Physician Assistant

NPI 1629474978 CMS profile 10854796

202 10Th St Se Ste 270, Cedar Rapids, IA 52403

Open in the dashboard

General payments

$10,044

507 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Aldrich of Cedar Rapids, IA is reported in the CMS Open Payments database as having received $10,044 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,012 100
2024 General $1,990 96
2023 General $2,413 125
2022 General $1,305 63
2021 General $2,325 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Aldrich
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Gary Aldrich were reported at $2,012. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Gary Aldrich Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,325 $111 $36–$285 $132
2022 $1,305 $126 $44–$350 $149
2023 $2,413 $137 $47–$355 $160
2024 $1,990 $146 $49–$384 $164
2025 $2,012 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,658 91 payments
  2. Sun Pharmaceutical Industries Inc. $1,461 58 payments
  3. Janssen Biotech, Inc. $1,091 56 payments
  4. Regeneron Healthcare Solutions, Inc. $660 22 payments
  5. Genzyme Corporation $656 23 payments
  6. Novartis Pharmaceuticals Corporation $628 41 payments
  7. Pfizer Inc. $570 36 payments
  8. Amgen Inc. $446 17 payments
  9. E.R. Squibb & Sons, L.L.C. $405 37 payments
  10. Galderma Laboratories, L.P. $326 21 payments
  11. Other $2,143 105 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,498 500 payments
  2. Education $546 7 payments
Products named General payments · program years 2021–2025
  1. ILUMYA $1,032 41 payments
  2. TREMFYA $941 48 payments
  3. DUPIXENT Immunology $904 30 payments
  4. RINVOQ $715 38 payments
  5. SKYRIZI $668 38 payments
  6. DUPIXENT Inflammation And Immunology $537 18 payments
  7. Otezla $446 17 payments
  8. CIBINQO $382 23 payments
  9. SOTYKTU $377 35 payments
  10. EUCRISA $310 20 payments
  11. Other $5,223 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

372

Median for Physician Assistant: 241

Drug cost

$138,977

Median for Physician Assistant: $4,110

Branded share of claims

6.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Etanercept Brand 11 $84,105
Dupixent Pen Dupilumab Brand 12 $44,726
Fluorouracil Generic 56 $3,700
Ketoconazole Generic 76 $1,430
Tacrolimus Generic 17 $1,386
Metronidazole Generic 24 $1,139
Clobetasol Propionate Generic 23 $803
Fluconazole Generic 51 $380
Desonide Generic 13 $377
Triamcinolone Acetonide Generic 36 $304

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$62,121

Medicare's payments for the services billed

Medicare patients

590

Average age 75

Services billed

2,211

163 women, 427 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 43%
Ischemic heart disease 25%
Diabetes 22%
Atrial fibrillation 18%
Chronic kidney disease 17%
Cancer 17%
Depression 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $164
  • GENZYME CORPORATION $113
$276 12 —
RINVOQ
  • AbbVie, Inc. $228
$228 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $193
$193 — —
SKYRIZI
  • AbbVie, Inc. $177
$177 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $156
$156 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record